Study uncovers inflammatory markers that may predict a response in certain patients to COVID-19 immunotherapies
Researchers have uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results.